Novo Nordisk Q1 Profit Beats As Wegovy Shrugs Off Compounding Headwind

Novo Nordisk reported first-quarter operating profit of DKK 53.8 billion, comfortably ahead of consensus and approximately 14% higher year-on-year, with Wegovy volumes accelerating in international markets as the US compounding headwind eased through the quarter.

The Danish drugmaker raised full-year guidance for both revenue and operating profit at constant currencies, with the new ranges sitting roughly two percentage points above the previous bands at both the top and the bottom. CFO Karsten Munk Knudsen attributed the upgrade primarily to faster-than-expected market expansion in Brazil, China, and the Gulf, where Wegovy launches that began in late 2025 have run ahead of internal forecasts.

The compounding question, which has dominated the earnings narrative for two years, is now genuinely receding. The FDA's decision in late 2025 to remove semaglutide from the official drug-shortage list closed the regulatory pathway compounding pharmacies had been operating under, and the volume of compounded GLP-1 prescriptions has fallen sharply through the first quarter. Novo's own data, citing third-party prescription analytics, suggests the compounded share of the US market has roughly halved since November.

The pipeline picture is also strengthening. The CagriSema phase-three readout, expected before year-end, remains the single most-watched datapoint for the company across the medical and investor communities. Beyond that, the oral-amycretin programme has progressed cleanly through the dose-finding work, and the rare-blood-disease franchise has held up well given the ongoing strategic decision to focus capital on the cardiometabolic platform.

For investors, the more important framing question is on margin durability. The company is investing aggressively in capacity — both organically and through the controlling family-foundation Catalent acquisition — and the cost trajectory through 2027 will inevitably feel the weight of that. But the demand-side picture is durable enough that the consensus model for 2026 and 2027 has more room to move higher than to compress.